Table 1.
Medicines and pharmaceutical products with the highest sales in Brazil, according to their active ingredient(s) and therapeutic indication(s).
| Ranking | Pharmaceuticals Products | Therapeutic Indication |
|---|---|---|
| 1 | Dorflex® (dipyrone monohydrate, orphenadrine citrate, and caffeine) | To relieve pain associated with muscle contractures, including tension headache |
| 2 | Xarelto® (rivaroxaban) | To prevent venous thromboembolism in adult patients undergoing elective knee or hip arthroplasty surgery |
| 3 | Saxenda® (liraglutide) | Chronic weight control in adults with a Body Mass Index of 27 kg/m2 or more |
| 4 | Neosaldina® (dipyrone, isometheptene mucate, and anhydrous caffeine) | To treat various types of headache, including migraines, or for the treatment of colic |
| 5 | Addera D3® (cholecalciferol) | Auxiliary treatment of bone demineralization (removal of minerals) before and after menopause, rickets, osteomalacia, osteoporosis and in the prevention of falls and fractures in older adults with vitamin D deficiency |
| 6 | Glifage XR® (metformin hydrochloride) | To treat type 2 diabetes in adults, alone or in combination with other oral anti-diabetics. Also used to treat type 1 diabetes in addition to insulin therapy and indicated to treat Polycystic Ovary Syndrome |
| 7 | Torsilax® (caffeine, carisoprodol, diclofenac sodium and paracetamol) | To treat rheumatism in its acute and chronic inflammatory-degenerative forms: acute gout crisis, acute inflammatory, post-traumatic and post-surgical states, acute exacerbations of rheumatoid arthritis or other rheumatic arthropathies, osteoarthritis, and acute states of rheumatism in extra-articular tissues, low back pain or low back pain. Also, an adjunct to severe inflammatory processes resulting from infectious conditions |
| 8 | Victoza® (liraglutide) | Chronic weight control in adults with a Body Mass Index (BMI) of 27 kg m-2 or more |
| 9 | Anthelios® (avobenzone, homosalate, octisalate, octocrylene and oxybenzone) | Sun protection |
| 10 | Puran T-4® (sodium levothyroxine) | In patients with hypothyroidism of any etiology (except for transient hypothyroidism, during the recovery phase of subacute thyroiditis), a replacement therapy or hormonal supplementation. Suppression of pituitary TSH in the treatment or prevention of various euthyroid goiter types, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s thyroiditis), thyroid-dependent follicular and papillary carcinomas. Upon diagnosis in suppression tests, aiding in the diagnosis of suspected mild hyperthyroidism or an autonomous thyroid gland. |
| 11 | Selozok® (metoprolol succinate) | Arterial hypertension: reduction in blood pressure, morbidity, and risk of mortality from the cardiovascular and coronary origin (including sudden death); Angina pectoris; Adjuvant in the therapy of symptomatic chronic heart failure, mild to severe; Changes in heart rhythm, including especially supraventricular tachycardia; Maintenance treatment after myocardial infarction; Functional cardiac changes with palpitations; Migraine prophylaxis |
| 12 | Aradois® (losartan potassium) | To treat hypertension and the treatment of heart failure when therapy with ACE inhibitors is no longer adequate. |
| 13 | Sal de Eno® (sodium bicarbonate, sodium carbonate and citric acid) | Relief from heartburn, poor digestion, and other stomach disorders, such as excess stomach acid and acid indigestion |
| 14 | Novalgina® (dipyrone monohydrate) | Analgesic and antithermic |
| 15 | Jardiance® (empagliflozin) | Diabetes mellitus type 2 |
| 16 | Alenia® (budesonide and formoterol) | To improve and control shortness of breath in patients with bronchoconstriction or bronchospasm in patients with bronchial asthma. |
| 17 | Prolopa® (levodopa and benserazide) | Parkinson’s disease |
| 18 | Galvus Met® (vildagliptin and metformin) | Diabetes mellitus type 2 |
| 19 | Ninho Fases 1+® (milk infant formula) | Food supplement |
| 20 | Venvanse® (tablisdexanfetamine) | Attention deficit hyperactivity disorder. |
Source: Interfarma, 2019; Sanofi, 2014; Bayer, 2018; Novo Nordisk, 2016; Takeda Pharma Ltd., 2013; Mantecorp Farmasa, 2019; Merck S/A, 2014; Neo Química, 2019; Novo Nordisk, 2014; Sanofi, 2020; AstraZeneca, 2018; Biolab, 2019; GlaxoSmithKline Brasil, 2019; Sanofi, 2017; Boehringer Ingelheim, 2018; Biosintetica, 2014; Produtos Roche Químicos e Farmacêuticos S.A., 2019; Novartis, 2018; Shire, 2019.